B. Riley analyst William Wood raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $670 from $560 and keeps a Buy rating on the shares. MASH is now valued using a risk-adjusted approach aligned with recent M&A deals, reflecting peak-year sales of $4.5B extended by loss of exclusivity protection and the Rezdiffra/’2086 combo strategy, the analyst tells investors in a research note. Early GLP-1 adoption trends and strong patient-level script growth support market expansion, while disciplined opex and modest gross-to-net adjustments underpin significant near-term free cash flow generation, the firm says.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
- Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals’ Rezdiffra
- Madrigal price target raised to $620 from $568 at H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $650 from $600 at Oppenheimer
- Madrigal Pharmaceuticals price target raised to $640 from $580 at Truist